Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Kastelein JJP, et al. Among authors: davidson mh. Curr Atheroscler Rep. 2024 Feb;26(2):35-44. doi: 10.1007/s11883-023-01184-1. Epub 2023 Dec 22. Curr Atheroscler Rep. 2024. PMID: 38133847 Free PMC article. Review.
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA; CAPTIVATE Investigators. Meuwese MC, et al. Among authors: davidson mh. JAMA. 2009 Mar 18;301(11):1131-9. doi: 10.1001/jama.301.11.1131. JAMA. 2009. PMID: 19293413 Clinical Trial.
CETP and SGLT2 inhibitor combination therapy improves glycemic control.
Khomtchouk BB, Sun P, Ditmarsch M, Kastelein JJP, Davidson MH. Khomtchouk BB, et al. Among authors: davidson mh. medRxiv [Preprint]. 2023 Jun 16:2023.06.13.23291357. doi: 10.1101/2023.06.13.23291357. medRxiv. 2023. PMID: 37398493 Free PMC article. Preprint.
Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN.
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Golberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh A, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH. Nicholls SJ, et al. Among authors: davidson mh. Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.05.002. Online ahead of print. Am Heart J. 2024. PMID: 38705341
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial.
Farina CJ, Davidson MH, Shah PK, Stark C, Lu W, Shirodaria C, Wright T, Antoniades CA, Nilsson J, Mehta NN. Farina CJ, et al. Among authors: davidson mh. Cardiovasc Res. 2024 Mar 25:cvae057. doi: 10.1093/cvr/cvae057. Online ahead of print. Cardiovasc Res. 2024. PMID: 38523341 No abstract available.
Toxicological safety assessment of HempChoice® hemp oil extract; a proprietary extract consisting of a high concentration of cannabidiol (CBD) in addition to other phytocannabinoids and terpenes derived from CannabissativaL.
Dziwenka M, Coppock R, Davidson MH, Weder MA. Dziwenka M, et al. Among authors: davidson mh. Heliyon. 2023 Jun 2;9(6):e16913. doi: 10.1016/j.heliyon.2023.e16913. eCollection 2023 Jun. Heliyon. 2023. PMID: 37313165 Free PMC article.
365 results